Saffron, stigmas of the purple crocus flower, is one of the most intriguing plants on Earth. It only blooms once a year and has only three stigmas when it does, making it one of the world’s most expensive spices by weight. It takes about 170,000 flowers to produce a single pound of saffron. Saffron is… Read More »
Recent studies suggest that the burden of menopausal symptoms is greater than generally perceived. About 80% of women experience vasomotor symptoms (VMS) – hot flashes and night sweats — as they transition into the menopause phase. For many, the symptoms are manageable; however, a significant proportion of midlife women experience menopausal symptoms that negatively affect… Read More »
One key characteristic of clinical depression is anhedonia, the complete lack of pleasure in things and activities that used to be rewarding. A new study in rats has now uncovered an important biological factor that contributes to this state. Researchers have found a new ‘key player’ in depression, and the discovery could lead to therapies… Read More »
I’m lying on a mattress on the floor, watching the ceiling turn into a doorway of thighbones. Outside, trees grow into monsters, but I’m not scared. How can I be? I don’t even know who I am – I’ve just ripped up my name and thrown it into the fire. I was at the end… Read More »
FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression Print this page March 19, 2019 — The U.S. Food and Drug Administration today approved Zulresso (brexanolone) injection for intravenous (IV) use for the treatment of postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD. “Postpartum depression… Read More »
The first drug for women suffering postpartum depression received federal approval on Tuesday, a move likely to pave the way for a wave of treatments to address a debilitating condition that is the most common complication of pregnancy. The drug works very quickly, within 48 hours — a significant improvement over currently available antidepressants, which… Read More »
January 30, 2019 from ObGynNews The last decade has brought appropriate attention to the high prevalence of postpartum mood and anxiety disorders, with postpartum depression (PPD) constituting the most common complication in modern obstetrics. There have been very substantial efforts in more than 40 states in the United States to enhance screening for PPD and… Read More »